GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Net Margin %

BOLD (Boundless Bio) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Boundless Bio's Net Income for the three months ended in Dec. 2024 was $-16.45 Mil. Boundless Bio's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Boundless Bio's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Boundless Bio's Net Margin % or its related term are showing as below:


BOLD's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -122.29
* Ranked among companies with meaningful Net Margin % only.

Boundless Bio Net Margin % Historical Data

The historical data trend for Boundless Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Net Margin % Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Margin %
- - - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Boundless Bio's Net Margin %

For the Biotechnology subindustry, Boundless Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boundless Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Net Margin % falls into.


;
;

Boundless Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Boundless Bio's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-65.363/0
= %

Boundless Bio's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-16.448/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boundless Bio  (NAS:BOLD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Boundless Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.